Anti-Mouse CD279 (PD-1) Purified
The J43.1 monoclonal antibody specifically reacts with mouse CD279, also known as PD-1 (programmed death-1), a 50-55 kDa glycoprotein of the Ig superfamily. The PD-1 ligands, PD-L1 (B7-H1) and PD-L2 (B7-H2) are members of the B7 family. Pd-1 contains an Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM) and influences the peripheral tolerances and autoimmune diseases in mice. PD-1 is transiently expressed on CD4/CD8 thymocytes, it is upregulated in apoptotic cells, and it is expressed by activated myeloid and T and B cells.
The binding of PD-1 to its ligands is blocked by the J43 antibody, which also enhances contact hypersensitivity and exacerbates acute Graft-versus-host disease, Experimental autoimmune encephalomyelitis and NOD diabetes. PD-1 seems to downregulate the immune response, as the development of splenomegaly and breakdown of peripheral tolerance in PD-1 deficient mice suggests.
FC, FA, IHC, IP
Armenian Hamster IgG
|Research Interest:||Adaptive Immunity, Apoptosis|
|Cell Type:||B Cells, T Cells|
|Application:||FC, FA, IHC, IP|
The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.
Nishimura, H., Agata, Y., Kawasaki, A., Sato, M., Imamura, S., Minato, N., ... & Honjo, T. (1996). Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4–CD8–) thymocytes. International immunology, 8(5), 773-780.
Salama, A. D., Chitnis, T., Imitola, J., Ansari, M. J. I., Akiba, H., Tushima, F., ... & Khoury, S. J. (2003). Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. The Journal of experimental medicine, 198(1), 71-78.
Carreno, B. M., & Collins, M. (2002). The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annual review of immunology, 20(1), 29-53.